Study of an oral medication for myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of myasthenia gravis (MG) that is moderate to severe (class II, III, or IV).
- You must have a positive blood test for AChR or MuSK antibodies.
- You must be able to swallow tablets (pills).
- Your weight must be at least 88 lbs (40 kg) and your BMI must be between 18 and 35.
- If you are able to become pregnant, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study follows people with suspected or confirmed myasthenia gravis (a condition that causes muscle weakness that gets worse with use). It uses several specialized nerve and antibody tests to make a more precise diagnosis and tracks you over time to see how well these methods work.
This study uses wearable sensors to track symptoms of myasthenia gravis in daily life. The goal is to see if these devices can better monitor how the disease changes over time.
This study tests a new medicine called IM-101 in people with myasthenia gravis (MG), a muscle weakness condition. It aims to see if it can safely help manage symptoms.
This study tests a smartphone-based digital tool that helps check symptoms in people with generalized myasthenia gravis (MG). It may help patients and clinicians track how the disease is doing over time using simpler, repeated assessments.
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.